MedTrace Logo

Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome

NCT02917512 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2018-04-12

No results posted yet for this study

Summary

A multicenter, Placebo controlled, Restasis® referenced, Randomized, Double blind, Phase II Study to Evaluate the Efficacy and Safety of HU00701/HU007 Eye Drops in Adult Patients with Dry Eye Syndrome

Conditions

  • Dry Eye Syndrome

Interventions

DRUG

HU00701

Cyclosporine 0.01% + 3% trehalose

DRUG

HU007

Cyclosporine 0.02% + 3% trehalose

DRUG

Restasis

Cyclosporine 0.05%

DRUG

Placebo

Vehicle

Sponsors & Collaborators

  • Huons Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Seung-il Baek · Huons Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02917512 on ClinicalTrials.gov